SCHEMBL1603335

SCHEMBL1603335

NCCC(=O)Oc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 1/20 0.56
PRSS2 P07478 1/20 0.56
PRSS3 P35030 1/20 0.56
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
HSD17B10 Q99714 2/20 0.50
CYP19A1 P11511 1/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
EGFR P00533 1/20 0.46
ERBB2 P04626 1/20 0.46
ELANE P08246 1/20 0.46
TAAR1 Q96RJ0 1/20 0.45
NSD2 O96028 1/20 0.44
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALOX15 P16050 2/20 0.43
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL10492687 0.98 PRSS1 (0.54) PRSS1PRSS2PRSS3KMT2AALDH1A1
Hydrochloric Acid SCHEMBL2002135 0.98 PRSS1 (0.54) PRSS1PRSS2PRSS3KMT2AALDH1A1
SCHEMBL1450488 0.90 PRSS1 (0.59) PRSS1PRSS2PRSS3KMT2AALDH1A1
SCHEMBL43742 0.89 KMT2A (0.61) PRSS1PRSS2PRSS3KMT2AALDH1A1
SCHEMBL27659306 0.88 PRSS1 (0.62) PRSS1PRSS2PRSS3KMT2AALDH1A1
Hydrochloric Acid SCHEMBL320656 0.88 PRSS1 (0.58) PRSS1PRSS2PRSS3KMT2AALDH1A1
SCHEMBL27920690 0.88 PRSS1 (0.58) PRSS1PRSS2PRSS3KMT2AALDH1A1
SCHEMBL8517366 0.87 PRSS1 (0.65) PRSS1PRSS2PRSS3KMT2AALDH1A1
SCHEMBL30593894 0.86 KMT2A (0.59) PRSS1PRSS2PRSS3KMT2AALDH1A1
Bromide SCHEMBL11186851 0.85 PRSS1 (0.63) PRSS1PRSS2PRSS3KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250000832-A1 ENHANCED NITRATE, ELEMENTAL METAL, AND AMINO ACID COMPOSITIONS AND METHODS OF USE THERMOLIFE INT LLC (US) 2025-01-02 US claimed
EP-4304389-A1 ENHANCED NITRATE, ELEMENTAL METAL, AND AMINO ACID COMPOSITIONS AND METHODS OF USE Thermolife International, LLC (US) 2024-01-17 EP claimed
WO-2022192743-A1 ENHANCED NITRATE, ELEMENTAL METAL, AND AMINO ACID COMPOSITIONS AND METHODS OF USE THERMOLIFE INTERNATIONAL, LLC (US) 2022-09-15 WO claimed
US-10736916-B1 Methods of improving athletic performance with inorganic nitrate compositions THERMOLIFE INTERNATIONAL, LLC (US) 2020-08-11 US claimed
CN-109097117-A A kind of energy-saving and environment-friendly gasoline comburant and preparation method thereof 杭州中齐新材料科技有限公司 2018-12-28 CN claimed
CN-108042811-A For treating the conjugate of the disease as caused by PSMA expression cells 恩多塞特公司 2018-05-18 CN claimed
CN-104768381-B Herbicidal combinations comprising chlorine Fampridine acid and bentazone 美国陶氏益农公司 2017-10-31 CN claimed
CN-104768376-B Herbicidal composition comprising aminopyralid and propanil 美国陶氏益农公司 2017-05-17 CN claimed
CN-104797247-A Conjugates for treating diseases caused by PSMA-expressing cells ENDOCYTE INC 2015-07-22 CN claimed
CN-102977098-B Aryl-substituted indolizine derivative and preparation method and applications thereof UNIV SHAOXING 2015-04-01 CN claimed
CN-102008459-B Antibacterial agents BIOTA SCIENT MAN 2013-05-29 CN claimed
CN-102977098-A Aryl-substituted indolizine derivative and preparation method and applications thereof UNIV SHAOXING 2013-03-20 CN claimed
CN-101857551-A Preparation method of o-aminoemthylbenzeneacetic acid (intermediate of ceforanide) JINTAN SANFANG MEDICINE RAW MATERIAL CO LTD 2010-10-13 CN claimed
CN-101380317-A Pharmaceutical composition for relieving pruritus CAYMAN ISLAND SHANGANSHENG DEV (CN) 2009-03-11 CN claimed
EP-0550866-B1 Process for the preparation of vinyl-substituted aromatics from arylamines HOECHST AG (DE) 1996-10-09 EP claimed
US-5475176-A Process for preparing vinyl-substituted aromatic compounds from arylamines HOECHST AKTIENGESELLSCHAFT (DE) 1995-12-12 US claimed
CN-1029932-C Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers BIORESEARCH INC (US) 1995-10-11 CN claimed
CN-1088908-A The chemical process of preparation 2-(2-aminomethyl phenyl)-3-methoxy-methyl acrylate ZENECA LTD (GB) 1994-07-06 CN claimed
EP-0550866-A2 Process for the preparation of vinyl-substituted aromatics from arylamines HOECHST AKTIENGESELLSCHAFT (DE) 1993-07-14 EP claimed
US-20250222143-A1 TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2025-07-10 US disclosed
US-20250205372-A1 RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2025-06-26 US disclosed
US-12194023-B2 Compositions and methods for modular control of bioorthogonal ligation THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2025-01-14 US disclosed
EP-3736275-B1 OXABICYCLOHEPTANE PRODRUGS FOR USE IN TREATING CANCER LIXTE BIOTECHNOLOGY INC (US) 2024-07-03 EP disclosed
US-11866444-B2 Oxabicycloheptane prodrugs LIXTE BIOTECHNOLOGY, INC. (US) 2024-01-09 US disclosed
WO-2023178313-A2 RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-09-21 WO disclosed
WO-2023070004-A1 TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-04-27 WO disclosed
US-20220235066-A1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY, INC. 2022-07-28 US disclosed
US-20220218661-A1 COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2022-07-14 US disclosed
US-11236102-B2 Oxabicycloheptane prodrugs LIXTE BIOTECHNOLOGY, INC. (US) 2022-02-01 US disclosed
US-20210276971-A1 TRIAZAMACROCYCLE-DERIVED CHELATOR COMPOSITIONS FOR COORDINATION OF IMAGING AND THERAPY METAL IONS AND METHODS OF USING SAME THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2021-09-09 US disclosed
CN-113150030-A Oxabicycloheptane prodrugs 莱克斯特生物技术公司 2021-07-23 CN disclosed
CN-106279023-B 3,4, 5-trisubstituted pyrazole compound, preparation method, pharmaceutical composition and application 中国科学院上海药物研究所 2021-06-22 CN disclosed
CN-107708686-B Oxabicycloheptane prodrugs 莱克斯特生物技术公司 2021-02-19 CN disclosed
WO-2021001420-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2021-01-07 WO disclosed
EP-3736275-A1 OXABICYCLOHEPTANE PRODRUGS FOR USE IN TREATING CANCER Lixte Biotechnology, Inc. (US) 2020-11-11 EP disclosed
US-20200325151-A1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY, INC. 2020-10-15 US disclosed
WO-2020113077-A9 COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-08-13 WO disclosed
WO-2020113077-A1 COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2020-06-04 WO disclosed
US-10618908-B2 Oxabicycloheptane prodrugs LIXTE BIOTECHNOLOGY, INC. (US) 2020-04-14 US disclosed
EP-3294287-B1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY INC (US) 2020-04-08 EP disclosed
CN-106715690-B Main-objective metal organic framework system 联邦科学和工业研究组织 2019-10-18 CN disclosed
US-10364252-B2 Oxabicycloheptane prodrugs LIXTE BIOTECHNOLOGY, INC. (US) 2019-07-30 US disclosed
CN-109843907-A Recombinate Microcystin production 新南创新有限公司 2019-06-04 CN disclosed
CN-105585601-B Anti-aging skin external composition and preparation method thereof 株式会社林原 2018-11-13 CN disclosed
US-20180244690-A1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY, INC. (US) 2018-08-30 US disclosed
US-9988394-B2 Oxabicycloheptane prodrugs LIXTE BIOTECHNOLOGY INC. (US) 2018-06-05 US disclosed
CN-108042811-A For treating the conjugate of the disease as caused by PSMA expression cells 恩多塞特公司 2018-05-18 CN disclosed
EP-3319139-A1 PHOTOELECTRIC CONVERSION ELEMENT, SOLAR BATTERY, AND COMPOSITION Fujifilm Corporation (JP) 2018-05-09 EP disclosed
US-20180108492-A1 PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL, AND COMPOSITION FUJIFILM CORPORATION (JP) 2018-04-19 US disclosed
US-20180108492-A1 PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL, AND COMPOSITION FUJIFILM CORPORATION (JP) 2018-04-19 US disclosed
EP-3294287-A1 OXABICYCLOHEPTANE PRODRUGS Lixte Biotechnology, Inc. (US) 2018-03-21 EP disclosed
CN-107708686-A Oxabicycloheptane prodrugs 莱克斯特生物技术公司 2018-02-16 CN disclosed
US-9872919-B2 Prodrugs for selective anticancer therapy THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2018-01-23 US disclosed
CN-106715690-A Host-guest metal organic framework systems 联邦科学和工业研究组织 2017-05-24 CN disclosed
CN-104781295-B Addition-fragmentation agents 3M创新有限公司 2017-03-08 CN disclosed
CN-106279023-A 3,4,5-tri-substituted pyrazolecarboxylic compounds, preparation method, pharmaceutical composition and purposes 中国科学院上海药物研究所 2017-01-04 CN disclosed
WO-2016186963-A1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY, INC. (US) 2016-11-24 WO disclosed
US-20160333024-A1 OXABICYCLOHEPTANE PRODRUGS LIXTE BIOTECHNOLOGY, INC. (US) 2016-11-17 US disclosed
US-20160184459-A1 CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2016-06-30 US disclosed
CN-105585601-A Anti-aging skin external composition and preparation method thereof HAYASHIBARA CO 2016-05-18 CN disclosed
CN-104918603-A Anti-aging skin external composition and preparation method thereof HAYASHIBARA CO 2015-09-16 CN disclosed
US-20150224208-A1 NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2015-08-13 US disclosed
CN-104797247-A Conjugates for treating diseases caused by PSMA-expressing cells ENDOCYTE INC 2015-07-22 CN disclosed
CN-102977098-B Aryl-substituted indolizine derivative and preparation method and applications thereof UNIV SHAOXING 2015-04-01 CN disclosed
WO-2015021305-A1 CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE THE RESEARCH FOUNDATION FOR THE STATE UNIVERISTY OF NEW YORK (US) 2015-02-12 WO disclosed
WO-2014047199-A1 NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2014-03-27 WO disclosed
CN-103370063-A Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules IMMUNOMEDICS INC 2013-10-23 CN disclosed
CN-102977098-A Aryl-substituted indolizine derivative and preparation method and applications thereof UNIV SHAOXING 2013-03-20 CN disclosed
CN-102898442-A Refinement method of ceforanide HENAN ZHONGSHUAI PHARMA CEUTICAL SCI & TECH DEV CO LTD 2013-01-30 CN disclosed
CN-1858931-B Lithium rechargeable battery SAMSUNG SDI CO LTD 2012-05-30 CN disclosed
CN-101071280-B Electrophotographic photoreceptor, and image forming apparatus and process cartridge using the same RICOH CO LTD 2012-05-16 CN disclosed
CN-102459265-A Pyrimidine inhibitors of kinase activity ABBOTT LAB 2012-05-16 CN disclosed
CN-101941982-B Novel preparation method of pharmaceutical ceforanide SICHUAN IND INST ANTIBIOTICS CHINA NAT PHARMACEUTICAL GROUP CORP 2012-03-14 CN disclosed
EP-2377579-A1 Cyclic peptide CXCR4 antagonists Eli Lilly and Company (US) 2011-10-19 EP disclosed
WO-2011121077-A1 MULTISENSOR ARRAY FOR DETECTION OF ANALYTES OR MIXTURES THEREOF IN GAS OR LIQUID PHASE DANMARKS TEKNISKE UNIVERSITET (DK) 2011-10-06 WO disclosed
EP-2160221-B1 CYCLIC PEPTIDE CXCR4 ANTAGONISTS LILLY CO ELI (US) 2011-07-20 EP disclosed
CN-101458476-B Corona charger, and process cartridge and image forming apparatus using same RICOH CO LTD 2011-05-18 CN disclosed
US-RE42274-E1 Cyclic peptide CXCR4 antagonists ELI LILLY AND COMPANY (US) 2011-04-05 US disclosed
CN-101941982-A Novel preparation method of pharmaceutical ceforanide SICHUAN IND INST ANTIBIOTICS CHINA NAT PHARMACEUTICAL GROUP CORP 2011-01-12 CN disclosed
CN-101380317-B Pharmaceutical composition for relieving pruritus CAYMAN ISLAND SHANGANSHENG DEV PHARMACEUTICAL CO LTD 2010-12-08 CN disclosed
CN-101857551-A Preparation method of o-aminoemthylbenzeneacetic acid (intermediate of ceforanide) JINTAN SANFANG MEDICINE RAW MATERIAL CO LTD 2010-10-13 CN disclosed
US-20100130409-A1 CYCLIC PEPTIDE CXCR4 ANTAGONISTS ELI LILLY AND COMPANY (US) 2010-05-27 US disclosed
US-7691813-B2 Provided are lactam-cyclized peptide CXCR4 antagonists (g-coupled protein receptor inhibitors) and a ligand SDF-1 (stromal cell-derived factor-1) useful in the in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection ELI LILLY AND COMPANY (US) 2010-04-06 US disclosed
EP-2160221-A1 CYCLIC PEPTIDE CXCR4 ANTAGONISTS Eli Lilly & Company (US) 2010-03-10 EP disclosed
CN-101458476-A Corona charger, and process cartridge and image forming apparatus using same RICOH KK (JP) 2009-06-17 CN disclosed
CN-101380317-A Pharmaceutical composition for relieving pruritus CAYMAN ISLAND SHANGANSHENG DEV (CN) 2009-03-11 CN disclosed
WO-2008150689-A1 CYCLIC PEPTIDE CXCR4 ANTAGONISTS ELI LILLY AND COMPANY (US) 2008-12-11 WO disclosed
US-20080300177-A1 CYCLIC PEPTIDE CXCR4 ANTAGONISTS ELI LILLY AND COMPANY 2008-12-04 US disclosed
WO-2008010043-A2 IMPROVED PROCESS FOR THE PREPARATION OF CEFORANIDE IN PURE FORM ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2008-01-24 WO disclosed
CN-101076330-A Octahydropyrano [3, 4-C ] pyrroles as tachykinin receptor antagonists MERCK & CO INC (US) 2007-11-21 CN disclosed
CN-101071280-A Electrophotographic photoreceptor, and image forming apparatus and process cartridge using the same RICOH KK (JP) 2007-11-14 CN disclosed
CN-101001860-A Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (CH) 2007-07-18 CN disclosed
CN-1858931-A Lithium rechargeable battery SAMSUNG SDI CO LTD (KR) 2006-11-08 CN disclosed
CN-1826325-A 4,5-dihydro-imidazole as P2X7 ion channel blockers AVENTIS PHARMA INC (US) 2006-08-30 CN disclosed
CN-1787989-A Imino ether derivative compound and medicine containing the same as active ingredient ONO PHARMACEUTICAL CO (JP) 2006-06-14 CN disclosed
CN-1202102-C Method for the production of 2-coumarone and substituted 2-coumarones DSM FINE CHEM AUSTRIA GMBH (AT) 2005-05-18 CN disclosed
CN-1608061-A Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2005-04-20 CN disclosed
US-20040192707-A1 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2004-09-30 US disclosed
WO-2004052879-A1 THIOPHENEDERIVATIVES FOR THE TREATMENT OF FLAVIVIRUS INFECTIONS VIROCHEM PHARMA INC. (CA) 2004-06-24 WO disclosed
CN-1136197-C Novel pyridajinone derivatives - 2004-01-28 CN disclosed
CN-1434815-A Method for the production of 2-coumarone and substituted 2-coumarones DSM FINE CHEM AUSTRIA GMBH (AT) 2003-08-06 CN disclosed
US-6521211-B1 Administering gases and ligand mixtures encapsulated in vesicles, scanning with ultrasonic frequency to oscillateand collapse the micelles, then detecting the reflected signals; medical diagnosis BRISTOL-MYERS SQUIBB MEDICAL IMAGING, INC. 2003-02-18 US disclosed
CN-1073109-C Tetrahydrofuran antifungals SCHERING CORP (US) 2001-10-17 CN disclosed
CN-1238760-A N- (aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions containing such compounds, and methods of inhibiting beta-amyloid peptide release and or synthesis using such compounds ELAN PHARM INC (US) 1999-12-15 CN disclosed
CN-1237960-A N (aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and method for inhibiting 'beta'-amyloid peptide release and/or its synthesis by use of such compounds YEELAN PHARMACEUTICAL CORP (US) 1999-12-08 CN disclosed
CN-1040425-C Chemical process ZENECA LTD (GB) 1998-10-28 CN disclosed
CN-1169426-A Novel pyridajinone derivatives HOFFMANN LA ROCHE (CH) 1998-01-07 CN disclosed
CN-1161038-A Tetrahydrofuran antifungals SCHERING CORP (US) 1997-10-01 CN disclosed
EP-0550866-B1 Process for the preparation of vinyl-substituted aromatics from arylamines HOECHST AG (DE) 1996-10-09 EP disclosed
US-5541229-A ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1996-07-30 US disclosed
US-5475176-A Process for preparing vinyl-substituted aromatic compounds from arylamines HOECHST AKTIENGESELLSCHAFT (DE) 1995-12-12 US disclosed
CN-1088908-A The chemical process of preparation 2-(2-aminomethyl phenyl)-3-methoxy-methyl acrylate ZENECA LTD (GB) 1994-07-06 CN disclosed
EP-0550866-A2 Process for the preparation of vinyl-substituted aromatics from arylamines HOECHST AKTIENGESELLSCHAFT (DE) 1993-07-14 EP disclosed
EP-0550866-A2 Process for the preparation of vinyl-substituted aromatics from arylamines HOECHST AKTIENGESELLSCHAFT (DE) 1993-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160184459-A1 CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE OR10J3, CCR3, GPR3 PRSS1 4430/4885PRSS2 4666/4885PRSS3 2978/4885
US-20100130409-A1 CYCLIC PEPTIDE CXCR4 ANTAGONISTS CXCR4, CXCR1, CXCL12 PRSS1 1175/4885PRSS2 2896/4885PRSS3 2926/4885
US-20220218661-A1 COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION CBR3, C1R, CBR1 PRSS1 3886/4885PRSS2 4133/4885PRSS3 3189/4885
US-20180108492-A1 PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL, AND COMPOSITION SCNN1A, CRY1, NR2E3 PRSS1 1793/4885PRSS2 1869/4885PRSS3 1990/4885
US-20250222143-A1 TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR PAICS, RABGGTB, PARP1 PRSS1 2512/4885PRSS2 4143/4885PRSS3 4504/4885
US-20150224208-A1 NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY NR4A3, ORC3, NTSR1 PRSS1 3848/4885PRSS2 4138/4885PRSS3 2442/4885
US-20220235066-A1 OXABICYCLOHEPTANE PRODRUGS UGT2B7, UGT1A6, UGT1A1 PRSS1 3619/4885PRSS2 4639/4885PRSS3 4709/4885
US-11866444-B2 Oxabicycloheptane prodrugs UGT2B7, UGT1A6, UGT1A1 PRSS1 3619/4885PRSS2 4639/4885PRSS3 4709/4885
US-12194023-B2 Compositions and methods for modular control of bioorthogonal ligation CBR3, C1R, CBR1 PRSS1 3886/4885PRSS2 4133/4885PRSS3 3189/4885
US-20200325151-A1 OXABICYCLOHEPTANE PRODRUGS UGT2B7, UGT1A6, UGT1A1 PRSS1 3619/4885PRSS2 4639/4885PRSS3 4709/4885
US-10618908-B2 Oxabicycloheptane prodrugs UGT2B7, UGT1A6, UGT1A1 PRSS1 3619/4885PRSS2 4639/4885PRSS3 4709/4885
US-20160333024-A1 OXABICYCLOHEPTANE PRODRUGS UGT2B7, UGT1A6, UGT1A1 PRSS1 3619/4885PRSS2 4639/4885PRSS3 4709/4885
US-20250205372-A1 RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT QPCT, SSTR5, SSTR4 PRSS1 3930/4885PRSS2 4531/4885PRSS3 4263/4885
US-20210276971-A1 TRIAZAMACROCYCLE-DERIVED CHELATOR COMPOSITIONS FOR COORDINATION OF IMAGING AND THERAPY METAL IONS AND METHODS OF USING SAME PAICS, SLC39A14, SLC39A7 PRSS1 4519/4885PRSS2 4728/4885PRSS3 4797/4885
US-20080300177-A1 CYCLIC PEPTIDE CXCR4 ANTAGONISTS CXCR4, CXCR1, CXCL12 PRSS1 1175/4885PRSS2 2896/4885PRSS3 2926/4885
US-20040192707-A1 Compounds and methods for the treatment or prevention of Flavivirus infections ZC3HAV1, HAVCR2, MAVS PRSS1 404/4885PRSS2 740/4885PRSS3 981/4885
US-10364252-B2 Oxabicycloheptane prodrugs UGT2B7, UGT1A6, UGT1A1 PRSS1 3619/4885PRSS2 4639/4885PRSS3 4709/4885
US-11236102-B2 Oxabicycloheptane prodrugs UGT2B7, UGT1A6, UGT1A1 PRSS1 3619/4885PRSS2 4639/4885PRSS3 4709/4885
US-20180244690-A1 OXABICYCLOHEPTANE PRODRUGS UGT2B7, UGT1A6, UGT1A1 PRSS1 3619/4885PRSS2 4639/4885PRSS3 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.